SARS neutralizing antibodies and SARS-CoV-2
A study showed that SARS neutralizing antibodies can successfully block SARS-CoV-2 entry into target cells in vitro, suggesting that the two viruses possess a cross-protective epitope and have similar immune protection against reinfection
0
2
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Vaccine Development for SARS-CoV References by Journal
Articles on SARS-CoV Vaccine Development
SARS neutralizing antibodies and SARS-CoV-2
Antibody Immune Response for SARS-CoV References by Journal/ Source
Epidemiology and Transmission Dynamics of SARS-CoV References by Journal
Epidemiology and Transmission Dynamics of SARS-CoV
References for Antibodies and COVID-19 by journal
SARS neutralizing antibodies and SARS-CoV-2
SARS-CoV-2 Antibodies and their uses in future SARS-CoV-2 Therapies
Types of Neutralizing Antibodies Targeting SARS-CoV-2 RBD of S protein
Non-RBD Targeted Antibodies
COVID-19 Recovery & Rehabilitation by Continent
References for COVID-19 Recovery & Rehabilitation Organized by Journal/Source
Transcriptome Profiling of COVID-19 Patients During Recovery Stage
Rehabilitation after critical illness in patients with COVID-19
SARS neutralizing antibodies and SARS-CoV-2
References for Secondary Infection of COVID-19 by Journal
Categories of Secondary Infections of COVID-19
SARS-CoV-2 and Human Immunodeficiency Virus (HIV) Co-infection
SARS-CoV-2 and Tuberculosis (TB) Co-infection
SARS neutralizing antibodies and SARS-CoV-2
SARS-CoV-2 and Dengue virus (DENV) in dengue‐endemic countries